Search
Perth children are being asked to volunteer for an important national study to test the effectiveness of an influenza vaccine in children.
More young Western Australians will have access to needle-free protection against influenza this winter, with the WA Government expanding its nation-leading FluMist® program to include teenagers aged 12 to 17 years.
New collaborative research involving almost 600,000 pregnant mothers has demonstrated a dramatic increase in uptake of the whooping cough (pertussis) vaccine after identifying just 22 per cent of WA women had the maternal vaccination between 2012 – 2017.
Babies worldwide could have access to life-saving influenza vaccinations from just eight weeks of age thanks to researchers at The Kids Research Institute Australia and the generous support of the Telethon community.
Infectious disease researchers who used a decade of scientific evidence to advocate for a nationwide childhood influenza immunisation policy have earned a finalist position at the country’s most prestigious science awards – the Australian Museum Eureka Prizes.
The Deborah Lehmann Research Award in Paediatric Infectious Disease Research is a funding mechanism to support the training and development of early- to mid-career researchers (EMCR) or Higher Degree by Research (HDR) students who are nationals from the Pacific Region working in or outside their hom
More children across Australia are being vaccinated against the flu since funding was expanded and access widened under the National Immunisation Program
Influenza vaccination is recommended for pregnant women, offering the dual benefit of protecting pregnant women and their newborn infants against influenza. This study aimed to investigate the impact of body mass index (BMI) on influenza vaccine responses in pregnant women and their newborns.
Respiratory Syncytial Virus (RSV) causes a significant burden of illness for children under 2 years of age. Nirsevimab, a long-acting monoclonal antibody, was registered for RSV prevention in Australia in 2023. In April 2024, Western Australia (WA) launched the country's first state-wide nirsevimab program for all infants and high-risk children entering their second RSV season.
Monitoring how the incidence of influenza infections changes over time is important for quantifying the transmission dynamics and clinical severity of influenza. Infection incidence is difficult to measure directly, and hence, other quantities which are more amenable to surveillance are used to monitor trends in infection levels, with the implicit assumption that they correlate with infection incidence.